- 专利标题： Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors
-
申请号： US16821674申请日： 2020-03-17
-
公开(公告)号： US11702472B2公开(公告)日： 2023-07-18
- 发明人: Prasad S. Adusumilli , Michel Sadelain , Dimiter S. Dimitrov , Yang Feng
- 申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , The U.S.A. as Represented by the Secretary, Department of Health and Human Services
- 申请人地址： US NY New York
- 专利权人： MEMORIAL SLOAN-KETTERING CANCER CENTER,THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- 当前专利权人： MEMORIAL SLOAN-KETTERING CANCER CENTER,THE U.S.A. AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- 当前专利权人地址： US NY New York; US MD Bethesda
- 代理机构： Baker Botts L.L.P.
- 分案原申请号： US15368278 2016.12.02
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; C07K14/725 ; C07K16/30 ; C07K14/705 ; C07K14/47 ; A61K39/00 ; A61K38/00 ; A61K35/00
摘要：
The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
公开/授权文献
- US20200239569A1 USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS 公开/授权日：2020-07-30
信息查询
